Şunu aradınız:: polysaccharide (İngilizce - Maltaca)

polysaccharide
polisakkaridu

haemophilus type b polysaccharide
polisakkarid tal- haemophilus tip b

haemophilus influenzae type b polysaccharide
polysaccharide haemophilus influenzae tat- tip b

pneumococcal polysaccharide serotype 11 2.2 µg
polysaccharide pnewmokokkali serotip 11 2.2 µg

pneumococcal polysaccharide serotype 11,2 1 microgram
polysaccharide pnewmokokkali serotip 11,2 mikrogramma waħda

haemophilus type b polysaccharide (polyribosylribitol phosphate)
polisakkarid haemophilus tip b (polyribosylribitol phosphate)

187 multivalent pneumococcal polysaccharide vaccine at week 4.
fi studju kliniku randomizzat, double blind, ikkontrollat bi plaċebo f’ pazjenti adulti b’ artrite psorjatika, 184 pazjenti ngħataw ukoll multivalent pneumococcal polysaccharide vaccine fir- 4 ġimgħa.

haemophilus type b polysaccharide (polyribosylribitol phosphate) 3
tip 1 (tar- razza mahoney) 4 tip 2 (tar- razza mef- 1) 4 tip 3 (tar- razza saukett) 4 haemophilus tip b polysaccharide (polyribosylribitol phosphate) 3

haemophilus influenzae type b polysaccharide conjugated to tetanus protein
haemophilus influenzae polysaccharide tip b konjugat għal proteina tat-tetnu

effect of prior vaccination with plain polysaccharide meningococcal vaccine
effett ta’ tilqima minn qabel b’vaċċin meningokokkali polysaccharide sempliċi

au haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 2
polysaccharide haemophilus influenzae tat- tip b (polyribosylribitol phosphate) 2

adults previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
adulti li preċedentement tlaqqmu bil-vaċċin polisakkaride pnewmokokkali ta’ 23-valenti

adults not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
adulti li ma kinux tlaqqmu qabel bil-vaċċin polisakkaride pnewmokokkali ta’ 23-valenti

42%), reduced rates to pneumococcal polysaccharide vaccine (43% vs.
42%), u rati

type b capsular polysaccharide (prp) and tetanus toxoid (t), adsorbed
capsular polysaccharide (prp) konjugat ma ’ toxoid tat- tetnu (t), adsorbit

adults 18-49 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
adulti li kellhom 18-49 sena li fil- passat ma ġewx imlaqqma b’tilqima tal-polysaccharide pnewmokokkali ta’ 23 valent

haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 3 micrograms conjugated to meningococcal protein2 50 micrograms
haemophilus influenzae tip b polysaccharide (polyribosylribitol phosphate) 3 mikrogrammi ikkonjugat mal-proteina meningokokkali2 50 mikrogramma

synflorix suspension for injection in pre-filled syringe pneumococcal polysaccharide conjugate vaccine (adsorbed)
synflorix suspensjoni għall-injezzjoni f’siringa mimlija għal-lest vaċċin konjugat (adsorbit) ta’ polysaccharide pnewmokokkali

haemophilus influenzae type b polysaccharide 12 micrograms (polyribosylribitol phosphate) conjugated to tetanus protein 22-36 micrograms
haemophilus influenzae polysaccharide tip b 12 il mikrogramma (polyribosylribitol phosphate) konjugat għal proteina tat-tetnu 22-36 mikrogramma

water soluble soybean polysaccharides
e 426